Mandy Jackson

Mandy Jackson

Managing Editor, US Commercial News

San Diego, CA

Mandy reports on daily biopharma developments, writes feature stories and produces Scrip's Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy. Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.

Latest from Mandy Jackson

Finance Watch: Atlas Raises Another $450m Fund To Back Start-Ups

Private Company Edition: Atlas Venture closed its $450m Fund XIV after some notable exits. Also, Nuvig’s $161m series B round more than triples its $47m series A from 2022, while Maze’s $115m series D fell below its prior $190m round and Antag raised an €80m ($84.7m) series A.

Genentech Finds Another Nanoparticle Partner In COUR

Deal Snapshot: Genentech will pay $40m up front and in the near term, with milestone fees of up to $900m-plus, to use COUR’s tolerogenic nanoparticle treatments in an undisclosed autoimmune disease.

Finance Watch: PIPEs Still Key Even As FOPO Fundraising Climbs

Public Company Edition: Biomedtracker data show the amount of money raised in both PIPEs and follow-on offerings surging in 2024. Olema and Cidara raised $250m and $105m, respectively, in recent private placements, while Spyre and Replimune grossed $200m and $140m in FOPOs.

Finance Watch: CEO Bischofberger Exits As Kronos Cuts 83% Of Workforce

Restructuring Edition: Kronos is laying off most of its employees as it considers strategic options, including a potential sale of its assets. Also, Agenus is restructuring and other companies revealed job cuts in Q3 earnings reports, including Sensei, AN2, NextCure and Aurinia.

Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For

Much anticipated Phase II results in obesity for Amgen’s GLP-1 agonist/GIP antagonist showed up to 20% weight loss, but without detailed data the drug’s competitiveness is hard to ascertain.

Cassava’s Alzheimer’s Drug Fails In First Phase III, Second Pivotal Trial Stopped

After years of controversy, simufilam did not achieve statistical significance on any endpoints in ReThink-ALZ, so the company ended ReFocus-ALZ and its long-term extension study.